Weber on Oncology

Jeffrey S. Weber, MD, PhD, is deputy director of the Perlmutter Cancer Center at NYU Langone in New York City, where he specializes in melanoma and cancer immunotherapy. He is the principal investigator of several ongoing studies funded by the National Cancer Institute, including trials in clinical drug development and the management of autoimmune side effects of immunotherapy for melanoma. He has also published more than 150 articles in top peer-reviewed journals.

+ Add to Email Alerts

ESMO 2021 Melanoma Update: 3 Important Trials from ESMO 2021 Dr Jeffrey Weber discusses recent melanoma studies presented at ESMO 2021.
Medscape Oncology, December 22, 2021
ASCO 2021 New Long-term Melanoma Data 'Clearly Favor' IPI/NIVO Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.
Medscape Oncology, August 03, 2021
ASCO 2021 What's Next After Anti-PD-1 Therapy for Melanoma Fails? Dr Jeffrey Weber describes two studies with encouraging results for patients with advanced melanoma that has not responded to anti-PD-1 and other immunotherapies.
Medscape Oncology, July 29, 2021
ASCO 2021 NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma ASCO studies validate dual LAG-3 and PD-1 inhibition in advanced melanoma, with good tolerability profiles, says Jeffrey Weber.
Medscape Oncology, July 01, 2021
Studies Back Neoadjuvant Strategies for Melanoma Two analyses of neoadjuvant immunotherapy support more rigorous study with RCTs of neoadjuvant vs adjuvant strategies for melanoma, says Dr Weber.
Medscape Oncology, March 24, 2021
'Impressive Results' From Stage III Melanoma Studies: ASCO 2020 Dr Jeffrey Weber describes three adjuvant and/or neoadjuvant studies in stage III melanoma that piqued his interest at this year's American Society of Clinical Oncology virtual meeting.
Medscape Oncology, August 25, 2020
Re-treating Melanoma After PD-1 Blockade Shows Good Response In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? A recent study addresses this important question.
Medscape Oncology, July 22, 2020
Searching for Biomarkers to Better Guide Melanoma Therapy Dr Jeffrey Weber explores the phase 3 COMBI-AD melanoma trial. Could tumor mutational burden alone or in combination with interferon gamma gene signature be a prognostic factor?
Medscape Oncology, June 03, 2020
BRAF/MEK Combo Yields 'Impressive' 5-Year Survival in Melanoma Roughly one third of advanced melanoma patients who start out with dabrafenib plus trametinib will do well long-term, Dr Weber reports.
Medscape Oncology, September 16, 2019
Response to Initial IO Treatment Predicts Melanoma Outcomes Patients with a brisk initial response to PD-1 antibody treatment may need only one dose of treatment, says Dr Weber.
Medscape Oncology, September 11, 2019
CheckMate 204 Update: Practice-Changing for Brain Metastases? New data show that ipilimumab plus nivolumab can produce a long-term response in patients with melanoma and brain metastases, says Dr Jeffrey Weber.
Medscape Oncology, September 09, 2019
Improved Safety Profile With 'Flip Dose' Nivo/Ipi Regimen Dr Jeffrey Weber discusses results from the CheckMate 511 trial, which demonstrated decreased adverse events with a revised dosing approach.
Medscape Oncology, July 05, 2019
Does Neoadjuvant pCR in Melanoma Predict Better Outcomes? Jeffrey Weber discusses recent trials investigating neoadjuvant combination immunotherapy in patients with melanoma.
Medscape Oncology, April 16, 2019
In Melanoma, IO plus HDAC Inhibitor Yields 'Impressive Results' Jeffrey Weber comments on a promising approach for heavily pretreated melanoma patients that was recently presented at the 2019 AACR annual meeting.
Medscape Oncology, April 11, 2019
CheckMate 204: 'Practice-Changing' for Metastatic Melanoma The ipilimumab plus nivolumab combination gives patients a reasonable chance of CNS tumor regression, thus not requiring radiation, according to Jeffrey Weber.
Medscape Oncology, April 03, 2019
'Optimistic' Longer-term Outcomes for Metastatic Melanoma Targeted therapy and immunotherapy are showing promising longer-term outcomes in metastatic melanoma. Dr Weber reviews two new studies.
Medscape Oncology, March 21, 2019
'Compelling' Regimen for Resectable Advanced-Stage Melanoma Dr Weber reviews a new trial comparing neoadjuvant and adjuvant dual MEK/BRAF inhibition to standard of care in advanced resectable melanoma.
Medscape Oncology, August 16, 2018
Immunotherapy Complete Responses Suggest Metastatic Melanoma Cures Because complete response from pembrolizumab is durable, Dr Weber is predicting that a cure for melanoma may be possible.
Medscape Oncology, August 09, 2018
ASCO 2018 'Very Impressive' Overall Survival for Melanoma Combination Dr Weber discusses new 'intriguing' overall survival data on the COLUMBUS trial presented at ASCO 2018.
Medscape Oncology, July 26, 2018
AACR 2018 Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma Dr Jeffrey Weber discusses the results of the KEYNOTE-054 trial, which demonstrated clear benefit with adjuvant pembrolizumab in patients with stage III resected melanoma.
Medscape Oncology, July 17, 2018

No Results